In a lung cancer model, the anti-tumor effect of fruquintinib was enhanced and could reduce the tumor volume by more than 85% when used in combination with other targeted agents, such as c-MET inhibitors and TKIs, suggesting a combination therapy of its great potential [36]. Here, MET is linked to neoplasm.